Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

Mateos, María‐Victoria; Α. Dimopoulos, Meletios; Cavo, Michèle; Suzuki, Kenshi; Jakubowiak, Andrzej; Knop, Stefan; Doyen, Chantal; Lúcio, Paulo; Nagy, Zsolt; Kaplan, Polina; Pour, Luděk; Cook, Mark; Grosicki, Sebastian; H Crepaldi, Andre; Marina Liberati, Anna; Campbell, Philip; Shelekhova, Tatiana; Yoon, Sung‐Soo; Iosava, Genadi; Fujisaki, Tomoaki; Garg, Mamta; Chiu, Christopher; Wang, Jianping; Carson, Robin; Crist, Wendy; Deraedt, William; Nguyen, Huong; Qi, Ming; F. San Miguel, Jesús

doi:10.1056/nejmoa1714678

Public

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

Published in New England Journal of Medicine • Dec 12, 2017

Authors:

María‐Victoria Mateos

Meletios Α. Dimopoulos

Michèle Cavo

Abstract

BACKGROUND: The combination of bortezomib, melphalan, and prednisone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. Daratumumab has shown efficacy in combination with standard-of-care regimens in patients with r...

Subject

Daratumumab

Melphalan

Bortezomib

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!